Tran-Scell Biologics Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.42 Cr
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.55 Cr
- Revenue Growth -36.79%
- Profit Growth -17.51%
- Ebitda -82.80%
- Net Worth -12.26%
- Total Assets -9.74%
About Tran-Scell Biologics
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U85100TG2009PTC066172
- Company No.
066172
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Dec 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Tran-Scell Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhadra Dravida  | Managing Director | 07-Dec-2009 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Uday Chatterjee | Director | 11-May-2020 | Current |
| Vinayender Tulla | Director | 05-Oct-2015 | Current |
Asif Hasan  | Additional Director | 25-Jul-2024 | Current |
Financial Performance of Tran-Scell Biologics.
Tran-Scell Biologics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 36.79% decrease. The company also saw a substantial fall in profitability, with a 17.51% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tran-Scell Biologics?
In 2023, Tran-Scell Biologics had a promoter holding of 62.39% and a public holding of 37.61%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Venkateshwara Multiplexes Private LimitedVinayender Tulla is a mutual person
Canter Technologies Private LimitedVinayender Tulla is a mutual person
Quantiphi Analytics Solutions Private LimitedAsif Hasan is a mutual person
Transcell Biosciences Private LimitedSubhadra Dravida and Uday Chatterjee are mutual person
Ahammune Biosciences Private LimitedUday Chatterjee is a mutual person
Gostops Hospitality Private LimitedUday Chatterjee is a mutual person
Charges (Loans)
₹0
₹1.55 Cr
Charges Breakdown by Lending Institutions
- Andhra Pradesh State Financial Corporation : 1.55 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 May 2010 | Andhra Pradesh State Financial Corporation | ₹1.55 Cr | Satisfied |
How Many Employees Work at Tran-Scell Biologics?
Unlock and access historical data on people associated with Tran-Scell Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tran-Scell Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tran-Scell Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
